PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
238.00 - 242.07
140.53 - 242.25
26.77M / 38.44M (Avg.)
25.64 | 9.39
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
4.42%
Revenue growth under 50% of META's 8.93%. Michael Burry would suspect a deteriorating sales pipeline or weaker brand.
2.86%
Gross profit growth under 50% of META's 9.13%. Michael Burry would be concerned about a severe competitive disadvantage.
-3.37%
Negative EBIT growth while META is at 14.01%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-3.37%
Negative operating income growth while META is at 14.01%. Joel Greenblatt would press for urgent turnaround measures.
3.77%
Net income growth under 50% of META's 15.11%. Michael Burry would suspect the firm is falling well behind a key competitor.
2.78%
EPS growth under 50% of META's 15.28%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
2.86%
Diluted EPS growth under 50% of META's 15.49%. Michael Burry would worry about an eroding competitive position or excessive dilution.
0.25%
Share count expansion well above META's 0.38%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
0.23%
Diluted share count expanding well above META's 0.34%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
7.95%
OCF growth at 50-75% of META's 11.85%. Martin Whitman would question if the firm lags in monetizing sales effectively.
4.20%
FCF growth under 50% of META's 12.66%. Michael Burry would suspect weaker operating efficiencies or heavier capex burdens.
636.59%
10Y revenue/share CAGR 1.25-1.5x META's 517.45%. Bruce Berkowitz would investigate brand strength or geographical expansion fueling growth.
117.10%
5Y revenue/share CAGR under 50% of META's 517.45%. Michael Burry would suspect a significant competitive gap or product weakness.
46.28%
3Y revenue/share CAGR under 50% of META's 198.63%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
765.03%
10Y OCF/share CAGR above 1.5x META's 431.91%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
134.26%
Below 50% of META's 431.91%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
87.94%
3Y OCF/share CAGR under 50% of META's 223.32%. Michael Burry would worry about a significant short-term disadvantage in generating operational cash.
508.98%
Net income/share CAGR at 50-75% of META's 869.72%. Martin Whitman might question if the firm’s product or cost base lags behind.
74.31%
Below 50% of META's 869.72%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
65.35%
Below 50% of META's 433.13%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
721.96%
Equity/share CAGR of 721.96% while META is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
129.88%
Equity/share CAGR of 129.88% while META is zero. Bruce Berkowitz might see a minor advantage that could compound if the firm maintains positive net worth growth.
56.80%
Below 50% of META's 256.14%. Michael Burry suspects a serious short-term disadvantage in building book value.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-2.88%
Firm’s AR is declining while META shows 9.60%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
No Data
No Data available this quarter, please select a different quarter.
3.67%
Asset growth at 50-75% of META's 7.06%. Martin Whitman questions if the firm is lagging expansions or if the competitor invests more aggressively.
4.61%
50-75% of META's 7.00%. Martin Whitman suspects weaker earnings or capital allocation vs. the competitor.
-6.31%
We’re deleveraging while META stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
6.93%
R&D growth drastically higher vs. META's 5.19%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
8.67%
SG&A growth well above META's 3.97%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.